Pharma Mar, S.A. (BME:PHM)
Spain flag Spain · Delayed Price · Currency is EUR
80.45
-0.75 (-0.92%)
Apr 1, 2025, 3:46 PM CET

Pharma Mar Statistics

Total Valuation

Pharma Mar has a market cap or net worth of EUR 1.43 billion. The enterprise value is 1.32 billion.

Market Cap 1.43B
Enterprise Value 1.32B

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date Apr 25, 2025
Ex-Dividend Date Jun 12, 2024

Share Statistics

Pharma Mar has 17.57 million shares outstanding. The number of shares has decreased by -1.98% in one year.

Current Share Class n/a
Shares Outstanding 17.57M
Shares Change (YoY) -1.98%
Shares Change (QoQ) n/a
Owned by Insiders (%) 11.77%
Owned by Institutions (%) 8.64%
Float 12.74M

Valuation Ratios

The trailing PE ratio is 54.51 and the forward PE ratio is 34.89. Pharma Mar's PEG ratio is 0.31.

PE Ratio 54.51
Forward PE 34.89
PS Ratio 8.14
PB Ratio 6.85
P/TBV Ratio 6.88
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio 0.31
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 108.57, with an EV/FCF ratio of -147.27.

EV / Earnings 50.67
EV / Sales 7.57
EV / EBITDA 108.57
EV / EBIT 204.64
EV / FCF -147.27

Financial Position

The company has a current ratio of 3.03, with a Debt / Equity ratio of 0.25.

Current Ratio 3.03
Quick Ratio 2.29
Debt / Equity 0.25
Debt / EBITDA 4.19
Debt / FCF -5.68
Interest Coverage 2.62

Financial Efficiency

Return on equity (ROE) is 13.00% and return on invested capital (ROIC) is 1.63%.

Return on Equity (ROE) 13.00%
Return on Assets (ROA) 1.17%
Return on Invested Capital (ROIC) 1.63%
Return on Capital Employed (ROCE) 2.42%
Revenue Per Employee 349,710
Profits Per Employee 52,250
Employee Count 500
Asset Turnover 0.51
Inventory Turnover 0.18

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +179.92% in the last 52 weeks. The beta is -0.05, so Pharma Mar's price volatility has been lower than the market average.

Beta (5Y) -0.05
52-Week Price Change +179.92%
50-Day Moving Average 91.15
200-Day Moving Average 65.22
Relative Strength Index (RSI) 32.98
Average Volume (20 Days) 50,161

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Pharma Mar had revenue of EUR 174.86 million and earned 26.13 million in profits. Earnings per share was 1.49.

Revenue 174.86M
Gross Profit 166.67M
Operating Income 6.47M
Pretax Income 11.99M
Net Income 26.13M
EBITDA 10.07M
EBIT 6.47M
Earnings Per Share (EPS) 1.49
Full Income Statement

Balance Sheet

The company has 154.53 million in cash and 51.08 million in debt, giving a net cash position of 103.45 million or 5.89 per share.

Cash & Cash Equivalents 154.53M
Total Debt 51.08M
Net Cash 103.45M
Net Cash Per Share 5.89
Equity (Book Value) 208.36M
Book Value Per Share 11.86
Working Capital 167.55M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.03 million and capital expenditures -15.02 million, giving a free cash flow of -8.99 million.

Operating Cash Flow 6.03M
Capital Expenditures -15.02M
Free Cash Flow -8.99M
FCF Per Share -0.51
Full Cash Flow Statement

Margins

Gross margin is 95.32%, with operating and profit margins of 3.70% and 14.94%.

Gross Margin 95.32%
Operating Margin 3.70%
Pretax Margin 6.85%
Profit Margin 14.94%
EBITDA Margin 5.76%
EBIT Margin 3.70%
FCF Margin n/a

Dividends & Yields

This stock pays an annual dividend of 0.65, which amounts to a dividend yield of 0.80%.

Dividend Per Share 0.65
Dividend Yield 0.80%
Dividend Growth (YoY) 23.46%
Years of Dividend Growth 1
Payout Ratio 43.71%
Buyback Yield 1.98%
Shareholder Yield 2.78%
Earnings Yield 1.83%
FCF Yield -0.63%
Dividend Details

Stock Splits

The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.

Last Split Date Jul 22, 2020
Split Type Reverse
Split Ratio 0.0833333333

Scores

Pharma Mar has an Altman Z-Score of 5.16.

Altman Z-Score 5.16
Piotroski F-Score n/a